FDA panel conflicts of interest
This article was originally published in The Gray Sheet
Executive Summary
Reconciled FY 2006 FDA appropriations bill passes the House Oct. 28 with a "very watered-down" version of an advisory committee conflict-of-interest (CoI) provision, according to Rep. Maurice Hinchey (D-N.Y.), who succeeded in adding a CoI amendment to the original House bill in June. The final language requires that panel member conflicts of interest and waivers for conflicts be posted on FDA's website at least 15 days prior to a meeting or as soon as possible if the conflict is identified closer to the meeting date. Hinchey's amendment would have prohibited FDA from granting CoI waivers (1"The Gray Sheet" June 13, 2005, In Brief)...
You may also be interested in...
As FDA Posts Waivers, House Okays Bill To Ban Panel Members With Conflicts
FDA has begun publishing conflict of interest waivers on its website for outside experts prior to their participation in advisory panel meetings, even as lawmakers continue to push for legislation that would ban individuals with conflicts from participating at all
FDA budget
The House Appropriations committee passes the $18.4 bil. "Agriculture, Rural Development, FDA, and Related Agencies Appropriations" bill for FY 2007 on May 9. For the second year in a row, the legislation contains an amendment forwarded by Congressman Maurice Hinchey (D-N.Y.) that would prohibit scientists and doctors with conflicts of interest from serving on FDA advisory panels. In October 2005, Congress approved a reconciled version of the FY 2006 spending bill with a watered-down version of Hinchey's conflict-of-interest provision (1"The Gray Sheet" Oct. 31, 2005, In Brief). The FY 2007 bill, which allots $229 mil. for the Center for Devices and Radiological Health, will now be taken up by the full House (2"The Gray Sheet" Feb. 13, 2006, p. 6)...
Senate passes approps
Reconciled version of FY 2006 FDA appropriations bill (HR 2744) provides over $222.7 mil. to CDRH - "an increase of $7.8 mil. over the FY 2005 level" - and "fully funds FDA's device review program," AdvaMed says in a Nov. 4 release. The Senate agreed to the conference report Nov. 3 by an 81-18 vote. The House passed the same language Oct. 28 (1"The Gray Sheet" Oct. 31, 2005, In Brief)...